World Journal of Advanced Research and Reviews
eISSN: 2581-9615 CODEN (USA): WJARAI
Cross Ref DOI: 10.30574/wjarr
Journal homepage: https://wjarr.com/

(REVIEW ARTICLE)

Check for updates

Organiod-on-chip systems for drug screening and disease modeling

Praveen Kumar Dasari *, Harika Nandhikola, Lakshmi Rajaboina, Krishna Durga Peddini, Vishnu Vardhan Bellamkonda and Anil Gundepuri

Associate Professor, Mother Teresa Pharmacy College, Sathupally, Khammam, Telangana, India.

World Journal of Advanced Research and Reviews, 2026, 29(01), 229-233

Publication history: Received on 24 November 2025; revised on 03 December 2025; accepted on 05 January 2026

Article DOI: https://doi.org/10.30574/wjarr.2026.29.1.0006

Abstract

Organoid-on-chip systems represent a transformative advancement in preclinical research, offering an innovative platform that integrates the biological complexity of organoids with the precise microengineering of organ-on-chip technologies. These hybrid systems recreate physiologically relevant tissue microenvironments, enabling dynamic control of biochemical, mechanical, and fluidic conditions that closely mimic in vivo physiology. By incorporating patient-derived organoids onto microfluidic chips, organoid-on-chip platforms provide unprecedented opportunities for personalized drug screening, enabling the evaluation of drug efficacy, toxicity, and pharmacokinetics in models that retain individual-specific genetic and phenotypic characteristics. This approach enhances predictive accuracy compared with conventional 2D cell cultures and animal models, thereby reducing translational gaps in drug development. In disease modeling, organoid-on-chip technology allows for the simulation of complex human disease states, such as cancer progression, metabolic disorders, neurodegenerative diseases, and infectious diseases. The microfluidic environment supports long-term culture, real-time monitoring, and multi-organ interactions, facilitating deeper insights into disease mechanisms. Additionally, integration with sensors and imaging modalities enables high-resolution analysis of cellular responses and molecular pathways.Overall, organoid-on-chip systems offer a powerful, scalable, and physiologically relevant platform for drug discovery, toxicity assessment, and mechanistic disease studies. Their ability to simulate patient-specific responses positions them as a promising tool for precision medicine, accelerating the development of safer and more effective therapeutics.

Keywords: Organoid-on-chip; 2D cell cultures; Animal models; Disease modeling

1. Introduction

Organoid-on-chip systems combine two powerful technologies—organoids and microfluidic organ-on-chip platforms—to create highly realistic models of human tissues and organs. Organoids, developed from pluripotent or adult stem cells, naturally self-assemble into 3D structures that resemble miniature organs with functional cell types and tissue organization. While they offer superior biological relevance compared to traditional 2D cultures, their growth environment inside static culture plates limits nutrient supply, waste removal, mechanical stimulation, and vascular-like flow. Organ-on-chip devices address these limitations by providing precisely controlled microenvironments with continuous perfusion, mechanical cues, and compartmentalization. When organoids are integrated into these microfluidic systems, they gain enhanced maturation, improved viability, and more physiologically accurate behavior. This fusion allows scientists to observe real-time cellular responses, model complex diseases, and test drug effects under conditions that closely mimic the human body.Organoid-on-chip platforms have shown strong potential in cancer research, infectious disease modeling, neurological studies, and metabolic disorder investigations. They also support personalized medicine by using patient-derived cells, enabling individualized predictions of drug efficacy and toxicity. Overall, these systems represent a major step forward in creating more reliable, human-relevant preclinical models that can accelerate drug discovery, reduce animal testing, and ultimately improve clinical translation.

* Corresponding author: Praveen Kumar Dasari

1.1. Organoid Generation and Characterization

This initial step focuses on creating the biological component of the system.

- Cell Source Selection: Decide on the cell type, such as induced pluripotent stem cells (iPSCs), adult stem cells (ASCs), or patient-derived cells (PDOs), which is crucial for personalized medicine applications.
- 3D Organoid Culture: Detail the specific protocol for generating the organoids (e.g., gut, liver, brain) using Matrigel or a synthetic hydrogel matrix in a defined medium with necessary growth factors (e.g., Wnt, EGF, Noggin, R-spondin).

Organoid Characterization: Verify that the generated organoids structurally and functionally resemble the native organ. This involves:

- Morphological analysis: Imaging to confirm 3D structure and cell polarity.
- Immunohistochemistry/Immunofluorescence: Staining for organ-specific markers (e.g., epithelial markers, specific cell type markers).
- Gene Expression Analysis (e.g., qPCR, RNA-seq): Confirming the expression of key functional genes.

1.2. Microfluidic Chip Design and Fabrication

This stage focuses on developing the physical platform, or "chip."

- Chip Material: Specify the material, most commonly Polydimethylsiloxane (PDMS) due to its biocompatibility and optical clarity, or other polymers like polystyrene.
- Microchannel Design: Detail the architecture of the chip, including:
- Culture Chambers: Spaces designed to house the organoids, often including features like microwells or embedded hydrogel regions to guide organoid placement.
- Microchannels: Channels for continuous perfusion of culture medium, drugs, or toxins.
- Tissue-Tissue Interfaces: For certain models (like lung-on-a-chip), a porous membrane may be included to separate different cell types (e.g., epithelial and endothelial cells).
- Integration of Mechanical/Physical Cues: If relevant, include features to apply mechanical strain (e.g., cyclic stretching) or fluid shear stress to mimic the in vivo microenvironment.
- Fabrication Method: Describe the manufacturing process, such as soft lithography (for PDMS) or 3D printing.

1.3. Organoid-on-Chip Integration and Culture

This is where the biological and engineering components are combined.

- Seeding: Describe the method for transferring the pre-formed organoids (or stem cells for *in situ* differentiation) into the chip's culture chambers.
- Dynamic Culture Setup: Detail the system for continuous perfusion using external pumps (e.g., syringe pumps or peristaltic pumps) to provide a constant flow of media and remove waste, thereby mimicking in vivo blood flow. Specify flow rates, medium composition, and culture duration.
- Co-culture (if applicable): Detail the method for incorporating other cell types, such as immune cells, fibroblasts, or endothelial cells, to better model the native tissue microenvironment. For multi-organ-chips, describe how multiple organoid types are fluidically coupled.

1.4. Drug Screening or Disease Modeling Assays

The final stage outlines the core experiments performed with the platform.

1.4.1. For Drug Screening:

- Experimental Design: Define the treatment groups (e.g., control, vehicle, drug candidate at various concentrations, standard-of-care drug).
- Drug Administration: Describe how drugs are introduced via the microfluidic channels.
- Endpoint Analysis: Specify the metrics used to evaluate drug effect:
- Viability/Toxicity Assays: Measuring cell survival (e.g., using CellTiter-Glo or live/dead staining).
- Functional Assays: Measuring organ-specific functions (e.g., albumin secretion for liver, barrier integrity for gut/lung, beating frequency for heart).

- High-Content Imaging (HCI): Capturing phenotypic or morphological changes (e.g., organoid size, shape, nuclear count).
- IC50/EC50 Determination: Calculating the half-maximal inhibitory/effective concentration.

For Disease Modeling:

Disease Induction: Describe how the disease state is established (e.g., using patient-derived cells, introducing disease-specific mutations via gene editing, or administering a pathological stimulus like a toxin, pathogen, or inflammatory agent).

Phenotypic Readouts: Define the key disease traits being measured:

- Morphological changes: Observing characteristics like fibrosis, cyst formation, or altered tissue architecture.
- Biomarker analysis: Measuring the secretion of disease-relevant molecules (e.g., inflammatory cytokines, specific protein aggregates).
- Functional changes: Assessing impaired function characteristic of the disease (e.g., compromised barrier function, reduced beating, loss of selective filtration).
- Transcriptomic/Proteomic Analysis: Analyzing changes in gene or protein expression related to disease progression.

2. Discussion

The development of organoid-on-chip systems represents a significant milestone in the evolution of preclinical research, combining the biological realism of organoids with the microenvironmental precision of microfluidic organ-on-chip platforms. The findings and literature collectively indicate that these hybrid systems bridge the translational gap that has long limited conventional 2D cultures and animal models. By enabling physiologically relevant cell–cell interactions, perfusion-based nutrient transport, and dynamic mechanical cues, organoid-on-chip platforms closely mimic in vivo human physiology. This enhanced physiological relevance strengthens the predictive power of drug screening studies and improves the reliability of disease modeling outcomes.Compared to standalone organoids, the integration of microfluidics offers improved control over environmental parameters such as shear stress, oxygen gradients, and metabolite exchange, which are critical for maintaining tissue maturation and long-term stability. Consequently, organoid-on-chip systems demonstrate higher reproducibility and can sustain complex multi-tissue interactions, making them particularly suitable for modeling multi-organ diseases or studying systemic drug responses. Furthermore, the ability to incorporate real-time sensors allows continuous monitoring of electrophysiological activity, metabolic shifts, and barrier integrity—capabilities that traditional in vitro models lack.

The application of organoid-on-chip systems in drug discovery shows promising results, especially in predicting organ-specific toxicity, drug metabolism, and patient-specific therapeutic responses. For instance, liver and cardiac organoid-on-chip models have demonstrated increased accuracy in identifying drug-induced hepatotoxicity and cardiotoxicity—two leading causes of drug withdrawal in clinical trials. Additionally, the personalized nature of organoids derived from patient stem cells expands the opportunity for precision medicine, enabling individualized drug screening and treatment optimization.Despite their potential, several challenges remain. Technical limitations such as microfluidic device fabrication, cost, and the need for specialized expertise hinder widespread adoption in routine laboratory settings. Standardization is another major constraint; variations in organoid culture protocols and chip designs reduce reproducibility and make cross-platform comparisons difficult. Furthermore, although organoid-on-chip systems outperform traditional models, they still cannot fully replicate whole-body responses, immune system interactions, or long-term chronic disease progression. Addressing these gaps will require improved biomaterial engineering, integration of immune components, and development of multi-organ interconnected chip networks.

Looking forward, the convergence of organoid-on-chip technology with artificial intelligence, high-throughput screening, and automated manufacturing holds the potential to accelerate drug development pipelines and reduce costs. AI-driven analysis can further enhance predictive accuracy by extracting deep phenotypic signatures from chip data. As the technology matures, standardization guidelines, regulatory support, and industry partnerships will play key roles in promoting its clinical and pharmaceutical adoption.In summary, organoid-on-chip systems represent a transformative platform that holds the promise to reshape drug screening and disease modeling. While challenges persist, continuous technological advancements and interdisciplinary collaborations are expected to drive this field toward more robust, scalable, and clinically relevant applications.

3. Conclusion

Organoid-on-chip technology represents a significant advancement in preclinical biomedical research, offering a more physiologically relevant and predictive platform than traditional in vitro and animal models. By integrating the biological complexity of organoids with the microenvironmental control provided by microfluidics, these systems enable more accurate modeling of human tissue function, disease progression, and drug responses. The evidence highlights their superior ability to replicate key aspects of human physiology—such as dynamic fluid flow, mechanical stimuli, and real-time monitoring—thereby improving both reproducibility and translational value. In drug screening, organoid-on-chip platforms have demonstrated enhanced capabilities in detecting toxicity, assessing pharmacokinetics and pharmacodynamics, and evaluating patient-specific therapeutic responses. Similarly, their application in disease modeling has enabled deeper insights into complex disorders, including cancer, infectious diseases, and neurodegenerative conditions, offering new avenues for precision medicine. While the technology still faces challenges related to standardization, scalability, and cost, ongoing innovations in biomaterials, microfabrication, and automation are expected to address these limitations.Overall, organoid-on-chip systems have the potential to reshape the future of drug discovery and biomedical research. With continued interdisciplinary collaboration and regulatory support, these platforms may soon become integral components of personalized medicine, reducing drug development failures and contributing to more effective and safer therapies.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

[1] 1`Hayes DF and Schott AF. Personalized medicine: genomics trials in oncology. Translational American Clinical Association. 2015, 126, 133–143.

[2] Skardal, A., Shupe, T, & Atala, A. Organoid-on-a-chip systems for drug screening and disease modeling. Drug Discovery Today. 2016, 21(9), 1399-1411.

[3] Wang, Y, & Qin, J. Advances in human organoids-on-chips in biomedical research. Protein & Cell. 2023, 14(4), 243-259.

[4] Kang, Y. Liver sinusoid-on-a-chip:long-term layered co-culture of primary rat hepatocytes and endothelial cells in microfluidic platforms. Biotechnol.Bioeng. 2015, 112(12), 2571-2582.

[5] Cantrell MA and Kuo CJ. Organoid reodeling for cancer precision Medicine. Genome Med 2015, 7, 32.

[6] Hayes DF and Schott AF. Personalized Medicine; genomics trials in oncology. Trans. AM clin. climatol. Assoc. 2015, 126, 133-143.

[7] Barrile, R. Organ-on-chip recapitulates thrombosis induced by an anti-CD154 monoclonal antibody: translational potential of advanced microengineered systems. Clin. Pharmacol. Ther. 2018, 104, 1240–1248.

[8] Zhang, B. Advances in organ-on-a-chip engineering. Nat. Rev. Mater. 2018, 3, 257–278.

[9] Chen, Y. Advances in engineered three-dimensional (3D) body articulation unit models. Drug Des. Dev. Ther. 2022, 16, 213–235.

[10] Varone, A. A novel organ-chip system emulates three-dimensional architecture of the human epithelia and the mechanical forces acting on it. Biomaterials. 2021, 275, 120957.

[11] Baert, Y. A multi-organ-chip co-culture of liver and testis equivalents: a first step toward a systemic male reprotoxicity model. Hum. Reprod. 2020, 35, 1029–1044.

[12] Jing, B. Yan, L. Li, J. Luo, P. Ai, X. Tu, P. Functional Evaluation and Nephrotoxicity Assessment of Human Renal Proximal Tubule Cells on a Chip. Biosensors 2022, 12, 718

[13] Khati, V. Ramachandraiah, H. Pati, F. Svahn, H.A. Gaudenzi, G. Russom, A. 3D Bioprinting of Multi-Material Decellularized Liver Matrix Hydrogel at Physiological Temperatures. Biosensors 2022, 12, 521.

[14] Matthiesen, I. Nasiri, R. Tamashiro Orrego, A. Winkler, T.E. Herland, A. Metabolic Assessment of Human Induced Pluripotent Stem Cells-Derived Astrocytes and Fetal Primary Astrocytes: Lactate and Glucose Turnover. Biosensors 2022, 12, 839

[15] Akcay, G. Luttge, R. Microenvironments Matter. Advances in Brain-on-Chip. Biosensors 2023, 13, 551.

[16] Thomas, D.P. Zhang, J. Nguyen, N.-T. Ta, H.T. Microfluidic Gut-on-a-Chip: Fundamentals and Challenges. Biosensors 2023, 13, 136.

[17] Eivazzadeh-Keihan, R. Saadatidizaji, Z. Maleki, A. de la Guardia, M. Mahdavi, M. Barzegar, S. Ahadian, S. Recent Progresses in Development of Biosensors for Thrombin Detection. Biosensors 2022, 12, 767.

[18] Busek, M. Aizenshtadt, A. Amirola-Martinez, M.; Delon, L. Krauss, S. Academic User View: Organ-on-a-Chip Technology. Biosensors 2022, 12, 126.